🇺🇸 FDA
Patent

US 9169509

Topoisomerase 2b as a predictor of susceptibility to anthracycline-induced cardiotoxicity

granted A61KA61K31/704

Quick answer

US patent 9169509 (Topoisomerase 2b as a predictor of susceptibility to anthracycline-induced cardiotoxicity) held by The Board of Regents of the University of Texas System expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/704